Dubai, UAE – Global Pharma, a leading pharmaceutical manufacturer in the UAE and wholly owned by Dubai Investments, announced the signing of seven strategic Memoranda of Understanding with key industry partners, aimed at enhancing its capabilities in research and development, improving manufacturing processes, financing, and sustainability .

These partnerships are distributed across three main pillars: innovation and product development, manufacturing, efficiency and sustainability, and market access, financing and expansion, with the aim of enhancing Global Pharma’s efforts and capabilities across the various stages of the pharmaceutical value chain .

These memoranda define the frameworks for cooperation with leading partners in these areas, including: Zim Laboratories FZE and Molchem Chemicals Private Limited within the Innovation and Product Development pillar; Masipus, a subsidiary of Sunbar, Rockwell Automation, and 386 Sky Solar Energy Systems LLC within the Manufacturing, Efficiency, and Sustainability pillar; and Emirates Development Bank (EDB) , Mubadala Bio's Union Pharmaceuticals Company (IDS), and Emirates Drug Authority (EDE) within the Market Access, Finance, and Expansion pillar.

Commenting on the agreements, Mohammed Saeed Al Raqbani, Managing Director of Dubai Investments Industrial and Board Member of Global Pharma, said: “The pharmaceutical sector is based on an integrated system that combines innovation, manufacturing, and the development of a supportive environment. These memoranda demonstrate a trend towards enhancing local capabilities, transferring knowledge and technology, and developing a more resilient and competitive pharmaceutical sector in the UAE. Through Global Pharma, Dubai Investments continues to support initiatives that align with national priorities and contribute to creating long-term value for the healthcare sector.”

For his part, Dr. Basem Al-Barahmeh, CEO of Global Pharma, said: “At Global Pharma, we focus on translating these partnerships into tangible, practical results. Through our collaboration with Zim Laboratories FZE, we are developing our products and enhancing our R&D capabilities to produce innovative pharmaceutical formulations. Simultaneously, our partnership with Emirates Development Bank provides structured financing solutions that support our long-term expansion and increased production capacity . Operationally, our partnerships with Masipus and Rockwell Automation support the introduction of modern automation technologies and digital solutions, contributing to increased efficiency, improved quality, and enhanced real-time performance monitoring within our factories . Our collaboration with SkyScholar 386 enables the integration of clean energy solutions into our operations in a practical and measurable way, helping to improve efficiency and reduce our environmental impact . These partnerships, along with our collaboration in localization, regulation, and distribution, contribute to our ability to consistently deliver high-quality products while ensuring the long-term sustainability of our operations.” "The tall one."

The collaboration with the Emirates Drug Authority (EDE) contributes to supporting efforts to localize the pharmaceutical industry, harmonize regulatory frameworks, and enhance national drug security, which helps develop local manufacturing and ensure a stable supply in the country. Global Pharma's partnerships with Molchem Chemicals and Mubadala Bio's Union Pharmaceuticals Company (IDS) also contribute to strengthening localization and distribution capabilities, particularly in critical therapeutic areas, while improving the efficiency of supply chains nationwide .

The cooperation in the field of sustainability also includes the installation of a 612-kilowatt solar power plant on the roof of the company’s facilities in Dubai Investments Park. This plant is expected to generate about 25.3 gigawatt-hours of clean energy, while reducing carbon dioxide emissions by about 11,400 tons, which is equivalent to planting more than 21,700 trees .

About Global Pharma

Global Pharma, a wholly owned subsidiary of Dubai Investments, was established in 1998 and is a leading pharmaceutical company with a strong regional presence. Global Pharma commenced operations in the UAE in 2003 and further strengthened its presence in 2008 by expanding its production lines and launching new products in 14 countries across the GCC and Africa. Global Pharma currently operates two state-of-the-art manufacturing plants to supply pharmaceuticals to the Middle East and North Africa region. One plant manufactures beta-lactam penicillin for the production of amoxicillin and amoxiclav, while the other manufactures generic pharmaceuticals, enabling the development of various liquid and oral dosage forms to meet the needs of chronic disease patients. www.globalpharma.com

About ZIM Laboratories FZE
ZIM Laboratories FZE is a pharmaceutical company focused on research, development, and the manufacturing of innovative generic drugs. The company possesses advanced expertise in drug delivery systems and product innovation, supporting the development of high-value pharmaceutical solutions in various global markets . www.zimlab.in

About Emirates Development Bank (EDB)
The Emirates Development Bank (EDB) is the UAE's development finance institution, providing financial and non-financial support to promote economic diversification and industrial growth. The bank plays a vital role in supporting key sectors such as manufacturing and healthcare by offering tailored financing solutions and advisory services . www.edb.gov.ae

About Masibus (a subsidiary of Sonepar )
Masibus Automation and Instrumentation FZC , a subsidiary of the Sonepar Group, specializes in industrial automation and digital transformation solutions. The company supports various sectors in the Middle East by developing technologies that improve operational efficiency, enhance process control, and integrate systems . www.sonepar.com

About Rockwell Automation
Rockwell Automation is a global leader in industrial automation and digital transformation, providing advanced control systems, software, and data-driven solutions. The company works across various sectors, including pharmaceuticals, to enhance manufacturing efficiency, improve quality, and support process stability . www.rockwellautomation.com

About 386 Sky Solar Energy Systems LLC

386 Sky Solar Energy Systems LLC is a UAE-based provider of commercial and industrial solar energy solutions, offering rooftop and ground-based solar systems, as well as integrated solutions across the region. The company supports organizations in their transition to clean energy in line with sustainability and carbon neutrality goals . www.threeeightsix.me

About Union Pharmaceuticals (IDS) – Mubadala Bio
Union Pharmaceuticals (IDS) , a subsidiary of Mubadala Bio, is one of the leading providers of pharmaceutical distribution and logistics solutions in the UAE, offering integrated services including

The company manages the supply chain, storage, and distribution. It offers a range of medications across various therapeutic areas, facilitating access to healthcare and enhancing the efficiency of supply chains within the country . www.mubadalabio.com

About the Emirates Drug Establishment (EDE)
The Emirates Drug Authority (EDA) is the federal body responsible for regulating and supervising the pharmaceutical and medical products sector in the UAE, ensuring the availability of high-quality, safe, and effective medicines throughout the country . www.ede.gov.ae

About Dubai Investments PJSC

Dubai Investments is a leading UAE-based company listed on the Dubai Financial Market. It has a diversified portfolio of companies that generate sustainable financial returns for its shareholders . Established in 1995, Dubai Investments has become one of the largest investment companies in the UAE, successfully launching new projects and forging partnerships with dynamic entities, creating strategic investment opportunities across the region. With 15,724 shareholders, a paid-up capital of AED 4.25 billion, and total assets of AED 23.28 billion, the company leverages prudent investment and practical expertise to achieve expansion and serve as a reliable engine for growth in sectors such as real estate, manufacturing, healthcare, education, investments, and services. The company maintains a diversified portfolio of wholly and partially owned companies. Dubai Investments' interests and investments reflect its ongoing focus on business diversification to drive growth in line with evolving industry trends .

Dubai Investments focuses on leveraging market strengths while creating new and sustainable business opportunities through a long-term, strategic, and innovative approach, achieving sustainable returns and ultimately capital growth. The company adopts investment strategies that address the evolving needs of the economy and the communities in which it operates. Dubai Investments pursues growth through mergers and acquisitions and business expansion to achieve its strategic objectives and create value for its stakeholders . For more information, please visit: www.dubaiinvestments.com .

For more information, please contact:

Mohammed Al Shamsi

Investor Relations Manager

Dubai Investments PJSC

Email: mohammed.alshamsi@dubaiinvestments.com

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.